中国防痨杂志2024，Vol.46Issue(8)：874-876,3.DOI:10.19982/j.issn.1000-6621.20240191
世界卫生组织《耐药结核病和丙型病毒性肝炎治疗的联合管理(2024快讯版)》解读
Interpretation of World Health Organization's Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C:2024 Update
摘要
Abstract
On April 9,2024,the World Health Organization published the updated guidelines for the Co-administration of Treatments for Drug-resistant Tuberculosis and Hepatitis C,as part of a rapid communication effort.This paper elucidates key aspects of the guideline,detailing the epidemiological background,pivotal evidence underpinning the updates,and significant findings.A comprehensive summary and forthcoming steps for the guideline's advancement are presented.Additionally,the authors evaluate the practical applicability of these guidelines in Chinese clinical settings and propose areas for future research,aiming to enhance the management of these coexisting conditions.关键词
结核,肺/抗药性,细菌/肝炎,丙型/共病现象/疾病管理Key words
Tuberculosis,pulmonary/Drug resistance,bacterial/Hepatitis C/Comorbidity/Disease management分类
医药卫生引用本文复制引用
杨梁梓,张培泽,卢水华..世界卫生组织《耐药结核病和丙型病毒性肝炎治疗的联合管理(2024快讯版)》解读[J].中国防痨杂志,2024,46(8):874-876,3.基金项目
Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties(SZGSP010) （SZGSP010）
Shenzhen Clinical Research Center for Tuberculosis(20210617141509001) （20210617141509001）
Guangdong Clinical Research Center for Tuberculosis(2020B1111170014)广东省高水平临床重点专科基金深圳市配套经费资助(结核病科,SZGSP010) （2020B1111170014）
深圳市结核病临床研究中心(20210617141509001) （20210617141509001）
广东省感染性疾病(结核病)临床医学研究中心(2020B1111170014) （结核病）
